Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration

SAN DIEGO, PARSIPPANY, N.J. and INDIANAPOLIS, July 12 /PRNewswire/ –
Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced
today that the companies have entered into a strategic collaboration in the
United States to raise awareness about antiplatelet therapy and the role of
platelet function testing.

Several factors, including a patient’s genetic make-up, diabetic status, age,
weight and the use of certain other medications metabolized through the
cytochrome P450 pathway in the body may influence patient response to
antiplatelet medicines. Therefore, it is important that physicians understand
their options to determine if their use of a specific antiplatelet medicine is
having its intended effect.

Antiplatelet medicines help prevent blood platelets from sticking or clumping
together, reducing the likelihood that arteries will be blocked by a clot,
leading to a heart attack.

The focus of the collaboration is to educate healthcare professionals about the
availability and reliability of a rapid and easy-to-use platelet function test,
and to stress the importance of assessing each patient’s platelet response to
antiplatelet medications.

“By working closely with Daiichi Sankyo and Lilly, we hope to offer greater
understanding of platelet function testing as a means to help physicians assess
patients’ platelet response to antiplatelet therapy,” said Timothy I. Still,
President and CEO of Accumetrics.

“We believe physicians will want to know the specific effect of a patient’s
antiplatelet therapy and whether additional measures may be needed,” said
Rogelio Braceras, M.D., senior medical director, thrombosis at Daiichi Sankyo,
Inc. “In fact, a recent Clinical Alert from the American College of Cardiology
Foundation and American Heart Association noted that several ongoing studies are
being conducted to evaluate whether directly measuring the antiplatelet effect
might be useful to help tailor antiplatelet therapy for patients.”

This collaborative program will work to provide healthcare professionals
information about the factors that affect response to antiplatelet medication
and how platelet function testing works. Platelet function testing can be
measured at the point of care and provides quick insight to physicians about the
antiplatelet effect of a specific medicine. With this information, physicians
can make more informed treatment decisions.

“By using platelet function testing, physicians now have another tool to help
them manage their patients on antiplatelet therapy,” said Tiffany Olson, vice
president of Diagnostics, Eli Lilly and Company.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function
and enhancing quality of care for patients receiving antiplatelet therapies by
providing industry-leading and widely accessible diagnostic tests for rapid
platelet function assessment.

Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to
help physicians determine an individual’s response to multiple antiplatelet
agents. Addressing every major antiplatelet drug, including FDA-cleared products
for aspirin, P2Y12 inhibitors, and GP IIb/IIIa inhibitors, the VerifyNow System
is widely used in various clinical settings where antiplatelet medications are
prescribed to reduce the occurrence of future thrombotic events such as heart
attack and stroke. For more information about the Company and its products,
visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics,
Inc.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio of
marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for thrombotic
disorders and focused on the discovery of novel oncology and
cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has
created a “Hybrid Business Model,” which will respond to market and customer
diversity and optimize growth opportunities across the value chain. For more
information, please visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of
the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please
visit www.dsi.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information – for some of the world’s most urgent medical
needs. Additional information about Lilly is available at www.lilly.com.

SOURCE Accumetrics, Inc.